Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.35 USD | -0.05% |
|
-4.04% | -23.01% |
Jul. 01 | Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat | MT |
Jul. 01 | Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.36 for the current year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.01% | 1.24B | B- | ||
+18.91% | 67.35B | A- | ||
-4.79% | 45.56B | A- | ||
+23.39% | 44.14B | B+ | ||
+38.09% | 28.89B | A- | ||
+9.69% | 19.28B | C+ | ||
+15.26% | 17.32B | B+ | ||
-26.04% | 14.85B | A- | ||
-13.27% | 14.72B | B+ | ||
-29.84% | 12.07B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OEC Stock
- Ratings Orion S.A.